Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors

Inclusion Criteria: * Fully understand the study and voluntarily sign the informed consent form. * Male or female 18-75 years of age. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. * PART 1: Histologically confirmed unresectable locally advanced, recurrent, or metastatic solid tumors.PART 2 Cohort A: Histologically confirmed unresectable locally advanced, recurrent, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. Cohort B: Histologically confirmed unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma. Cohort C: Histologically confirmed unresectable locally advanced, recurrent, or metastatic other solid tumors. * Life expectancy ≥ 3 months. Exclusion Criteria: * participants were deemed unsuitable for participating in the study by the investigator for any reasons.